Matthew Ros

Matthew Ros is the Chief Operating Officer at Jasper Therapeutics , bringing more than 35 years of experience and a significant track record of demonstrated strategic, capital formation, operational and commercialization success within public and private biopharmaceutical companies evolving from early stage to registrational development and launch. Most recently, Mr. Ros served as Chief Operating Officer at Verastem Oncology (Nasdaq: VSTM), Prior to that, he served as Chief Executive Officer and board director at FORE Biotherapeutics, a private, early, clinical-stage oncology company focused on recurrent central nervous system malignancies. Previously, Mr. Ros held executive leadership roles at prominent biopharmaceutical companies, including Epizyme (Nasdaq: EPZM), Sanofi-Genzyme, and ARIAD Pharmaceuticals, where he built fully integrated organizations, delivered strategic collaborations, secured multiple FDA approvals, and successful launches. Mr. Ros began his career at Bristol-Myers Squibb where he held positions of increasing responsibility within its Oncology division, contributing to and championing the successful launches of many leading oncology brands. In addition to his executive experience, Mr. Ros currently serves as a board member at Cogent Biosciences (Nasdaq: COGT), contributing to its Audit, Nomination, and Governance Committees, and previously served on the Board of Trustees of CancerCARE. He obtained a B.S. from State University of New York at Plattsburgh.